A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer

por Patel, Manish R., Falchook, Gerald S., Hamada, Kensuke, Makris, Lukas, Bendell, Johanna C.
Publicado 2021

Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors

por Bendell, Johanna C., Patel, Manish R., Moore, Kathleen N., Chua, Cynthia C., Arkenau, Hendrik‐Tobias, Dukart, Gary, Harrow, Kim, Liang, Chris
Publicado 2018

Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors

por Bendell, Johanna C., Patel, Manish R., Yoshida, Kenichiro, Seraj, Jabed, Weaver, Racquel, Lemech, Charlotte, Todaro, Thomas G., Pant, Shubham, Arkenau, Hendrik-Tobias
Publicado 2016

A Phase II Study with Lead‐In Safety Cohort of 5‐Fluorouracil, Oxaliplatin, and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized...

por Shepard, Gregg, Arrowsmith, Edward R., Murphy, Patrick, Barton, John H., Peyton, James D., Mainwaring, Mark, Blakely, Laura, Maun, Noel A., Bendell, Johanna C.
Publicado 2017

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

por Bendell, Johanna C., Rosen, Lee S., Mayer, Robert J., Goldman, Jonathan W., Infante, Jeffrey R., Benedetti, Fabio, Lin, Donghu, Mizuguchi, Hirokazu, Zergebel, Christopher, Patel, Manish R.
Publicado 2015

Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

por Bendell, Johanna C., Rosen, Lee S., Mayer, Robert J., Goldman, Jonathan W., Infante, Jeffrey R., Benedetti, Fabio, Lin, Donghu, Mizuguchi, Hirokazu, Zergebel, Christopher, Patel, Manish R.
Publicado 2015

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors

por Pant, Shubham, Burris, Howard A., Moore, Kathleen, Bendell, Johanna C., Kurkjian, Carla, Jones, Suzanne F., Moreno, Ofir, Kuhn, John G., McMeekin, Scott, Infante, Jeffrey R.
Publicado 2013

Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohor...

por Burris, Howard A, Bakewell, Suzanne, Bendell, Johanna C, Infante, Jeffrey, Jones, Suzanne F, Spigel, David R, Weiss, Glen J, Ramanathan, Ramesh K, Ogden, Angela, Von Hoff, Daniel
Publicado 2017

Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer

por Yaung, Stephanie J., Ju, Christine, Gattam, Sandeep, Nicholas, Alan, Sommer, Nicolas, Bendell, Johanna C., Hurwitz, Herbert I., Lee, John J., Casey, Fergal, Price, Richard, Palma, John F.
Publicado 2022

A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

por Bendell, Johanna C., Zakari, Ahmed, Peyton, James D., Boccia, Ralph, Moskowitz, Mark, Gian, Victor, Lipman, Andrew, Waterhouse, David, LoCicero, Richard, Earwood, Chris, Lane, Cassie M., Meluch, Anthony
Publicado 2016

Phase 1, Open-Label, Dose Escalation, Safety, and Pharmacokinetics Study of ME-344 as a Single Agent in Patients With Refractory Solid Tumors

por Bendell, Johanna C, Patel, Manish R, Infante, Jeffrey R, Kurkjian, Carla D, Jones, Suzanne F, Pant, Shubham, Burris, Howard A, Moreno, Ofir, Esquibel, Vanessa, Levin, Wendy, Moore, Kathleen N
Publicado 2015

Regorafenib Prior to Selective Internal Radiation Therapy Using (90)Y-Resin Microspheres for Refractory Metastatic Colorectal Cancer Liver Metastases: Analysis of Safety, Dosimetry...

por Kennedy, Andrew, Shipley, Dianna, Shpak, Max, Blakely, Laura, Hemphill, Brian, Shih, Kent, Lane, Cassie, Zimmerman, Lisa, McKenzie, Andrew, Mainwaring, Mark, Peyton, James D., Zubkus, John, Wright, David, Singh, Jaswinder, Bendell, Johanna C.
Publicado 2019

Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers

por Klempner, Samuel J., Bendell, Johanna C., Villaflor, Victoria Meucci, Tenner, Laura LaNiel, Stein, Stacey M., Rottman, James B., Naik, Girish S., Sirard, Cynthia A., Kagey, Michael H., Chaney, Marya F., Strickler, John H.
Publicado 2021

A phase I study of ABT-510 plus bevacizumab in advanced solid tumors

por Uronis, Hope E, Cushman, Stephanie M, Bendell, Johanna C, Blobe, Gerard C, Morse, Michael A, Nixon, Andrew B, Dellinger, Andrew, Starr, Mark D, Li, Haiyan, Meadows, Kellen, Gockerman, Jon, Pang, Herbert, Hurwitz, Herbert I
Publicado 2013

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type...

por Eng, Cathy, Bessudo, Alberto, Hart, Lowell L., Severtsev, Aleksey, Gladkov, Oleg, Müller, Lothar, Kopp, Mikhail V., Vladimirov, Vladimir, Langdon, Robert, Kotiv, Bogdan, Barni, Sandro, Hsu, Ching, Bolotin, Ellen, von Roemeling, Reinhard, Schwartz, Brian, Bendell, Johanna C.
Publicado 2016

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors

por Wu, Huali, Infante, Jeffrey R, Keedy, Vicki L, Jones, Suzanne F, Chan, Emily, Bendell, Johanna C, Lee, Wooin, Kirschbrown, Whitney P, Zamboni, Beth A, Ikeda, Satoshi, Kodaira, Hiroshi, Rothenberg, Mace L, Burris, Howard A, Zamboni, William C
Publicado 2015

A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanc...

por Bendell, Johanna C., Kelley, Robin K., Shih, Kent C., Grabowsky, Jennifer A., Bergsland, Emily, Jones, Suzanne, Martin, Thomas, Infante, Jeffrey R., Mischel, Paul S., Matsutani, Tomoo, Xu, Shuichan, Wong, Lilly, Liu, Yong, Wu, Xiaoling, Mortensen, Deborah S., Chopra, Rajesh, Hege, Kristen, Munster, Pamela N.
Publicado 2015

A Randomized, Double‐Blinded, Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial

por Ko, Andrew H., Murphy, Patrick B., Peyton, James D., Shipley, Dianna L., Al‐Hazzouri, Ahmed, Rodriguez, Francisco A., Womack, Mark S., Xiong, Henry Q., Waterhouse, David M., Tempero, Margaret A., Guo, Shuangli, Lane, Cassie M., Earwood, Chris, DeBusk, Laura M., Bendell, Johanna C.
Publicado 2017

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

por Hassan, Raffit, Blumenschein, George R., Moore, Kathleen N., Santin, Alessandro D., Kindler, Hedy L., Nemunaitis, John J., Seward, Shelly M., Thomas, Anish, Kim, Stella K., Rajagopalan, Prabhu, Walter, Annette O., Laurent, Dirk, Childs, Barrett H., Sarapa, Nenad, Elbi, Cem, Bendell, Johanna C.
Publicado 2020

Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial

por Chau, Ian, Penel, Nicolas, Soriano, Andres O., Arkenau, Hendrik-Tobias, Cultrera, Jennifer, Santana-Davila, Rafael, Calvo, Emiliano, Le Tourneau, Christophe, Zender, Lars, Bendell, Johanna C., Mi, Gu, Gao, Ling, McNeely, Samuel Clark, Oliveira, Joana M., Ferry, David, Herbst, Roy S., Fuchs, Charles S.
Publicado 2020